Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML

CPX-351 is a liposomal formulation of cytarabine:daunorubicin designed to deliver synergistic drug ratios to leukemia cells. In this phase 2 study, newly diagnosed older acute myeloid leukemia (AML) patients were randomized 2:1 to first-line CPX-351 or 7+3 treatment. The goal was to determine effica...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Blood
Prif Awduron: Lancet, Jeffrey E., Cortes, Jorge E., Hogge, Donna E., Tallman, Martin S., Kovacsovics, Tibor J., Damon, Lloyd E., Komrokji, Rami, Solomon, Scott R., Kolitz, Jonathan E., Cooper, Maureen, Yeager, Andrew M., Louie, Arthur C., Feldman, Eric J.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society of Hematology 2014
Pynciau:
Clinical Trials and Observations
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4624448/
https://ncbi.nlm.nih.gov/pubmed/24687088
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-12-540971
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg